Cure8 research brief
This study provides real-world 12-month results for people with moderate-to-severe Crohn’s disease or ulcerative colitis treated with biologic or small-molecule therapies in Bahrain—showing many patients improved clinically, endoscopically, and biochemically but that hospitalizations and surgeries remained common.
It adds regional evidence about outcomes on advanced therapies.
Adult patients with moderate-to-severe IBD, clinicians treating IBD, researchers studying real-world biologic and small-molecule effectiveness, and patients currently on or considering biologic/small-molecule therapy.
This study summarizes real-world 12-month outcomes in a Gulf-region cohort of IBD patients treated with advanced therapies. The main findings are proportion achieving clinical and endoscopic remission, corticosteroid-free rates, and improvements in common biomarkers.
The analysis compared anti-TNF versus non–anti-TNF groups in exploratory, unadjusted analyses and found higher clinical remission and steroid-free rates with anti-TNF agents but no significant difference in endoscopic outcomes.
Limitations include the retrospective, single-center design, inclusion only of patients who stayed on therapy for 12 months with follow-up endoscopy (which can bias toward better outcomes), and lack of adjusted comparative analyses. The sample mixes CD and UC and reports substantial hospitalization and surgery rates despite therapy.
Readers should view this as useful regional real-world data that supports the effectiveness of advanced therapies but not definitive comparative efficacy; larger prospective, multicenter studies with standardized endpoints are needed.
The report is a retrospective, single-center treatment-completer cohort (only patients who remained on the same therapy for 12 months with follow-up endoscopy), which can overestimate effectiveness versus all patients starting therapy. Comparative findings between drug classes were exploratory and unadjusted.
The article provides an abstract-level summary rather than full trial registry details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
